Today, there are clear signs that the biopharmaceutical industry is facing a quiet yet potentially damaging force: compressive disruption.
Unlike “big bang” disruptions where companies are out-innovated by a competitor or new entrant, compressive disruption happens slowly and stealthily when a series of biopharma innovations, macroeconomic factors and other changes combine to squeeze profits over a decade or more.
However, future-focused biopharma companies have found a way to deliver exceptional growth amidst compressive disruption: by embracing New Science, an ever-evolving combination of the best in science and health technology that is filling unmet need and raising the standard of care.
Three signals of biopharma compression
These three signs of compressive disruption reveal a biopharmaceutical industry facing headwinds.
See how New science is reshaping the biopharma landscape.
New Science offers a more precise, effective way to treat and care for patients in ways previously not attainable. It unlocks a tremendous opportunity to drive significant growth across multiple therapeutic areas, from oncology to dermatology.
New Science will change the landscape in which innovative treatments are discovered, developed and brought to the patients that need them.
Find out how your organization can lead in New Science and make a difference in patients’ lives faster and better than ever before.